Jose Carlos Escobar

US Patent:

8268311, Sep 18, 2012

Filed:

Sep 18, 2008

Appl. No.:

12/675013

Inventors:

Jacqueline A. Kirchner - Seattle WA, US
Kenneth A. Brasel - Seattle WA, US
Kara Olson - White Plains NY, US
Jose Carlos Escobar - Sammamish WA, US
Dauphine Barone - Mill Creek WA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 39/395
A61K 39/00

US Classification:

4241331, 4241301, 4241411, 4241351, 4241421

Abstract:

Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.

US Patent:

8481704, Jul 9, 2013

Filed:

Aug 20, 2012

Appl. No.:

13/589935

Inventors:

Jacqueline A. Kirchner - Seattle WA, US
Kenneth A. Brasel - Seattle WA, US
Kara Olson - White Plains NY, US
Jose Carlos Escobar - Sammamish WA, US
Dauphine Barone - Mill Creek WA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07H 21/04
C12P 21/08
C12N 15/10

US Classification:

536 2353, 435 691, 4353201, 435325

Abstract:

Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.

US Patent:

20110002913, Jan 6, 2011

Filed:

Jul 1, 2010

Appl. No.:

12/829231

Inventors:

RICHARD J. ARMITAGE - BAINBRIDGE ISLAND WA, US
JOSE CARLOS ESCOBAR - SAMMAMISH WA, US
ARVIA E. MORRIS - SEATTLE WA, US
JOHN D. PLUENNEKE - PARKVILLE MO, US

International Classification:

A61K 39/395
C07K 16/00
C07H 21/04
A61P 11/06
A61P 19/02
A61P 37/08
C12N 15/63
C12N 5/10

US Classification:

4241301, 5303891, 5303873, 536 2353, 4353201, 435325, 435335

Abstract:

Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.

US Patent:

20130259799, Oct 3, 2013

Filed:

Jun 11, 2013

Appl. No.:

13/914905

Inventors:

Kenneth A. Brasel - Seattle WA, US
Kara Olson - White Plains NY, US
Jose Carlos Escobar - Sammamish WA, US
Dauphine Barone - Mill Creek WA, US

International Classification:

A61K 51/00
A61K 45/06
A61K 39/395

US Classification:

424 111, 5303892, 5303873, 53038823, 536 2353, 4353201, 435335, 435 696, 4241581

Abstract:

Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.

US Patent:

20190023798, Jan 24, 2019

Filed:

Oct 4, 2018

Appl. No.:

16/151781

Inventors:

- Thousand Oaks CA, US
Jose Carlos Escobar - Sammamish WA, US
Arvia E. Morris - Seattle WA, US
John D. Pluenneke - Parkville MO, US

Assignee:

IMMUNEX CORPORATION - Thousand OaksThousand Oaks CA

International Classification:

C07K 16/28
A61K 39/395
C07K 14/715
A61K 38/00
A61K 39/00

Abstract:

Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.

US Patent:

20180171016, Jun 21, 2018

Filed:

Feb 9, 2018

Appl. No.:

15/893101

Inventors:

- Thousand Oaks CA, US
Jose Carlos ESCOBAR - Sammamish WA, US
Arvia E. MORRIS - Seattle WA, US
John D. PLUENNEKE - Parkville MO, US

Assignee:

IMMUNEX CORPORATION - Thousand Oaks CA

International Classification:

C07K 16/28

Abstract:

Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.

US Patent:

20170137526, May 18, 2017

Filed:

Jan 24, 2017

Appl. No.:

15/414447

Inventors:

- THOUSAND OAKS CA, US
Jose Carlos ESCOBAR - Sammamish WA, US
Arvia E. MORRIS - Seattle WA, US
John D. PLUENNEKE - Parkville MO, US

Assignee:

IMMUNEX CORPORATION - THOUSAND OAKS CA

International Classification:

C07K 16/28

Abstract:

Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.

US Patent:

20140154267, Jun 5, 2014

Filed:

Feb 7, 2014

Appl. No.:

14/175943

Inventors:

- Seattle WA, US
Jose Carlos ESCOBAR - Sammamish WA, US
Arvia E. MORRIS - Seattle WA, US
John D. PLUENNEKE - Parkville MO, US

Assignee:

Immunex Corporation - Seattle WA

International Classification:

C07K 16/28

US Classification:

4241721, 5303891, 5303873, 536 2353, 4353201, 435334, 435 696

Abstract:

Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.